CHI's Structure-Based Drug Design

You will hear about developments in insilico technology, as well as experimental approaches useful for accurately predicting and modeling the structures of proteins in structure-based drug design efforts. In addition,examples of successful applications of such technology approaches to genome-to-drug lead investigations will be addressed.

Keynote Presentation

Drugging the Undruggable:
Transforming Nature's α-Helix into Breakthrough Medicines
Tomi Sawyer, Ph.D., CSO, Aileron Therapeutics